A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
2019년 2월 7일 업데이트: Eisai Inc.
An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.
연구 개요
연구 유형
중재적
등록 (실제)
173
단계
- 2 단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Arizona
-
Tucson, Arizona, 미국
-
-
California
-
Orange, California, 미국
-
San Diego, California, 미국
-
-
Florida
-
Tampa, Florida, 미국
-
-
Illinois
-
Joliet, Illinois, 미국
-
-
Kentucky
-
Louisville, Kentucky, 미국
-
-
Maryland
-
Annapolis, Maryland, 미국
-
Bethesda, Maryland, 미국
-
-
Massachusetts
-
Boston, Massachusetts, 미국
-
-
Mississippi
-
Tupelo, Mississippi, 미국
-
-
New York
-
New York, New York, 미국
-
-
Oklahoma
-
Tulsa, Oklahoma, 미국
-
-
South Carolina
-
Charleston, South Carolina, 미국
-
-
Texas
-
Dallas, Texas, 미국
-
-
-
-
-
Barcelona, 스페인
-
Cordoba, 스페인
-
Madrid, 스페인
-
Pamplona, 스페인
-
-
-
-
-
Bristol, 영국
-
Cambridge, 영국
-
Cardiff, 영국
-
Glasgow, 영국
-
Guildford, 영국
-
Ipswich, 영국
-
Leicester, 영국
-
London, 영국
-
Manchester, 영국
-
Southampton, 영국
-
Surrey, 영국
-
Wirral, 영국
-
-
-
-
-
Brno, 체코
-
Olomouc, 체코
-
Prague, 체코
-
-
-
-
-
Gdansk, 폴란드
-
Lodz, 폴란드
-
Szczecin, 폴란드
-
Warsaw, 폴란드
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Select Inclusion Criteria:
- Histologically confirmed diagnosis of renal cell carcinoma.
- Phase 2: Histological or cytological confirmation of predominant clear cell renal cell carcinoma (RCC) (original tissue diagnosis of RCC is acceptable).
- Documented evidence of unresectable advanced or metastatic RCC. Phase 2: Radiographic evidence of disease progression according to modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
- Phase 2: One prior vascular endothelial growth factor (VEGF)-targeted treatment (for example, but not limited to, sunitinib, sorafenib, pazopanib, bevacizumab, axitinib, vatalanib, AV951/tivozanib) for unresectable advanced or metastatic RCC.
- Phase 2: Measurable disease meeting the following criteria: a.) at least 1 lesion of greater than or equal to 1.5 cm in the longest diameter for a non-lymph node or greater than or equal to 1.5 cm in the short axis diameter for a lymph node which is serially measurable according to Modified RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI) or photography. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Screening Visit.
Select Exclusion Criteria:
Phase 1b or Phase 2 specific per below:
- Phase 1b only: Subjects with untreated or unstable metastasis to the central nervous system (CNS) are excluded. Subjects who have completed local therapy and have discontinued the use of steroids for this indication at least 4 weeks prior to commencing treatment and in whom stability has been proven by at least 2 CT or MRI scans obtained at least 4 weeks apart are eligible for Phase 1b only. Phase 2 only: Subjects with CNS (e.g., brain or leptomeningeal) metastasis are excluded.
- Phase 2 only: More than one prior VEGF-targeted treatment for unresectable advanced or metastatic RCC.
Phase 1b or Phase 2 specific per below:
- Phase 1b only: Prior exposure to lenvatinib. Phase 2 only: Prior exposure to lenvatinib or mammalian target of rapamycin (mTOR) inhibitor.
- Subjects should not have received any anticancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug and should have recovered from any toxicity related to previous anticancer treatment. Major surgery within 3 weeks prior to the first dose of study drug.
- Subjects having greater than 1+ proteinuria on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria.
- Subjects with urine protein greater than or equal to 1 g/24 hours will be ineligible. Uncontrolled diabetes as defined by fasting serum glucose at 1.5 x ULN.
- Phase 2 only: Active malignancy (except for renal cell carcinoma, melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24 months.
- Known intolerance to any of the study drugs (or any of the excipients) and/or known hypersensitivity to rapamycins (e.g., sirolimus, everolimus, temsirolimus) or any of the excipients.
- Phase 1b only: Subjects who discontinued prior tyrosine kinase inhibitor due to toxicity will be ineligible.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 렌바티닙
|
taken orally, once a day
다른 이름들:
|
|
실험적: Lenvatinib plus Everolimus
|
taken orally, once a day
다른 이름들:
taken orally, once a day
다른 이름들:
|
|
활성 비교기: Everolimus
|
taken orally, once a day
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT)
기간: First dose of study drug (Cycle 1 Day 1) to end of first 4 weeks of therapy (Cycle 1)
|
A DLT was defined as either a treatment-related failure to administer greater than or equal to (>=) 75% of the planned dosage of lenvatinib/everolimus or a specific National Cancer Institute Common Toxicity Criteria (NCI CTC) >= Grade 3 (severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care daily living activities) hematologic or nonhematologic toxicities considered to be possibly related to lenvatinib and/or everolimus therapy assessed during the first treatment cycle of each dose level.
Higher grade indicates more severe toxicity.
|
First dose of study drug (Cycle 1 Day 1) to end of first 4 weeks of therapy (Cycle 1)
|
|
Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 (RP2) Dose
기간: First dose of study drug (Cycle 1 Day 1) to end of Cycle 2 (1 cycle = 28 days/4 weeks)
|
The highest dose level resulting in 0 or 1 DLT in 6 participants was to be considered the MTD of Phase 1b.
Once the MTD was established, the participant cohort was expanded to a minimum of 10 participants.
The MTD was confirmed by assessing DLTs during Cycle 1 and intolerable toxicities (i.e., not manageable with dose interruption and/or reduction) during Cycle 2 of therapy.
Once the dose of lenvatinib/everolimus combination to be used in the succeeding Phase 2 part of the study was established, enrollment into Phase 2 was started.
The RP2 dose was the same as the confirmed MTD and was used for the Phase 2 Treatment Arm A of this study.
|
First dose of study drug (Cycle 1 Day 1) to end of Cycle 2 (1 cycle = 28 days/4 weeks)
|
|
Phase 2: Progression-Free Survival (PFS)
기간: Date of randomization into Phase 2 (Cycle 1 Day 1) to the date of first documentation of disease progression or death (whichever occurred first), assessed up to data cutoff date (13 Jun 2014), up to approximately 2 years and 3 months
|
PFS was defined as the time (in months) from the date of first dose of study drug to the first documentation of disease progression or death, whichever occurred first.
Kaplan-Meier (K-M) estimates were used to estimate median PFS, presented with 2-sided 95% confidence intervals (CIs).
Tumor assessments were performed every 8 weeks (or sooner if there was evidence of progressive disease using computed tomography (CT) or magnetic resonance imaging (MRI) and scan acquisition techniques (including use or nonuse of intravenous (IV) contrast).
Tumor response was determined at the site by the investigator and radiologist using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 in the evaluation of the tumor assessment scans.
The date of objective disease progression was defined as the earliest date of radiological disease progression.
Participants removed from therapy due to clinical progression with no radiologic confirmation were censored at their last radiologic assessment date.
|
Date of randomization into Phase 2 (Cycle 1 Day 1) to the date of first documentation of disease progression or death (whichever occurred first), assessed up to data cutoff date (13 Jun 2014), up to approximately 2 years and 3 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 2: Overall Survival (OS)
기간: Randomization (Cycle 1 Day 1) until date of death from any cause, assessed up to the data cutoff date (10 Dec 2014), up to approximately 2 years and 9 months
|
OS was defined as the time (in months) from the date of randomization until date of death from any cause.
Median survival time was calculated using K-M estimate for each treatment arm and presented with 2-sided 95% CIs.
Participants who were lost to follow-up or alive at the data cutoff date (10 Dec 2014) were censored at the date the participants were last known to be alive.
|
Randomization (Cycle 1 Day 1) until date of death from any cause, assessed up to the data cutoff date (10 Dec 2014), up to approximately 2 years and 9 months
|
|
Phase 2: Objective Response Rate (ORR)
기간: Randomization (Cycle 1 Day 1) until first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
The ORR was defined as the percentage of participants who had the best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator, using RECIST 1.1 in the evaluation of MRI or CT scans of targeted lesions.
Tumor assessments were performed every 8 weeks (or sooner if there was evidence of progressive disease).
The BOR was defined as the best response recorded from the start of the study treatment until discontinuation from the study.
CR was defined as disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm.
PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
ORR = CR + PR was calculated with exact 95% CIs using the method of Clopper and Pearson.
|
Randomization (Cycle 1 Day 1) until first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
|
Disease Control Rate (DCR)
기간: Baseline (Randomization) to first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
The DCR was defined as the percentage of participants who had a BOR of CR or PR or SD (minimum duration from randomization to SD greater than or equal to 7 weeks).
Assessments were performed every 8 weeks and were based on investigator review data using RECIST 1.1.
The 95% CI was constructed using the method of Clopper and Pearson.
DCR = CR + PR + SD greater than or equal to 7 weeks.
|
Baseline (Randomization) to first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
|
Durable Stable Disease (SD) Rate
기간: Baseline (Randomization) to first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
The durable SD rate was defined as the percentage of participants whose BOR was SD and the duration of SD was greater than or equal to 23 weeks.
The durable SD was based on investigator review data using RECIST 1.1.
The 95% CI was constructed using the method of Clopper and Pearson.
|
Baseline (Randomization) to first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
|
Clinical Benefit Rate (CBR)
기간: Baseline (Randomization) to first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
The CBR was defined as the percentage of participants who had BOR of CR, PR, or durable SD (duration of SD was greater than or equal to 23 weeks) and was based on investigator review data using RECIST 1.1.
The BOR was defined as the best response recorded from the start of study treatment until discontinuation from the study.
There was no requirement for confirmatory measurement of PR or CR to deem either one the BOR.
The 95% CI was constructed using the method of Clopper and Pearson.
CBR = CR + PR + SD greater than or equal to 23 weeks.
|
Baseline (Randomization) to first evidence of disease progression, assessed up to the data cutoff date (13 Jun 2014), or up to approximately 2 years and 3 months
|
|
Summary of Plasma Concentrations of Lenvatinib for Sparse Pharmacokinetic (PK) Sampling for Phase 1b and Phase 2
기간: Cycle 1 (Day 1), Cycle 2 (Day 1), Cycle 3 (Day 1)
|
Blood samples were collected during the Randomization Phase.
Most participants had 6 samples taken over 3 cycles of treatment (sparse sampling - 2 samples taken per cycle, one at predose and one at 2 to 8 hours postdose).
Plasma concentrations of lenvatinib were measured and concentration data were summarized.
The summary statistics at time points with one or more below the limit of quantitation (BLQ) values were calculated by assigning zero for each BLQ value.
|
Cycle 1 (Day 1), Cycle 2 (Day 1), Cycle 3 (Day 1)
|
|
Summary of Blood Concentrations of Everolimus for Sparse PK Sampling for Phase 1b and Phase 2
기간: Cycle 1 (Day 1), Cycle 2 (Day 1), Cycle 3 (Day 1)
|
Blood samples were collected during the Randomization Phase.
Most participants had 6 samples taken over 3 cycles of treatment (sparse sampling - 2 samples taken per cycle, one at predose and one at 2 to 8 hours postdose).
Whole blood concentrations of everolimus were measured and concentration data were summarized.
The summary statistics at time points with one or more BLQ values were calculated by assigning zero for each BLQ value.
|
Cycle 1 (Day 1), Cycle 2 (Day 1), Cycle 3 (Day 1)
|
|
Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC(0-24)) for Lenvatinib When Administered Alone or in Combination With Everolimus
기간: Phase 2: Cycle 1 Day 15 immediately predose, and 30 minutes, 1, 2, 3, 4, 8, 12 (optional), and 24 hours postdose (predose on Day 16)
|
Between 9 and 12 participants in each of the 3 treatment arms participated in an optional substudy where instead of the sparse sampling, 9 samples were to be taken over 1 single 24-hour period (i.e., intensive sampling) for full PK profiling.
Blood samples were analyzed for study drug using standardized methods.
PK parameters for lenvatinib were derived from lenvatinib concentration data using non-compartmental methods.
Data were compared via descriptive statistics between single agent and combination therapy.
|
Phase 2: Cycle 1 Day 15 immediately predose, and 30 minutes, 1, 2, 3, 4, 8, 12 (optional), and 24 hours postdose (predose on Day 16)
|
|
Maximum Concentration (Cmax) of Lenvatinib in Plasma When Administered Alone or in Combination With Everolimus
기간: Phase 2: Cycle 1 Day 15
|
Cmax for lenvatinib was defined as the maximum observed concentration of lenvatinib in plasma following administration of study treatment on Cycle 1 Day 15 and was obtained directly from the measured plasma concentration-time curves.
|
Phase 2: Cycle 1 Day 15
|
|
Time to Cmax (Tmax) for Lenvatinib When Administered Alone or in Combination With Everolimus
기간: Phase 2: Cycle 1 Day 15
|
Tmax for lenvatinib was the amount of time taken after administration of study treatment on Cycle 1 Day 15 to reach maximum concentration (Cmax) of lenvatinib in plasma.
|
Phase 2: Cycle 1 Day 15
|
|
Area Under the Blood Concentration-Time Curve From 0 to 24 Hours for Everolimus When Administered Alone or in Combination With Lenvatinib
기간: Phase 2: Cycle 1 Day 15 immediately predose, and 30 minutes, 1, 2, 3, 4, 8, 12 (optional), and 24 hours postdose (predose on Day 16)
|
Between 9 and 12 participants in each of the 3 treatment arms participated in an optional substudy where instead of the sparse sampling, 9 samples were to be taken over 1 single 24-hour period (i.e., intensive sampling) for full PK profiling.
Blood samples were analyzed for study drug using standardized methods.
PK parameters for everolimus were derived from everolimus concentration data using non-compartmental methods.
Data were compared via descriptive statistics between single agent and combination therapy.
|
Phase 2: Cycle 1 Day 15 immediately predose, and 30 minutes, 1, 2, 3, 4, 8, 12 (optional), and 24 hours postdose (predose on Day 16)
|
|
Maximum Concentration of Everolimus (Cmax) in Blood When Administered Alone or in Combination With Lenvatinib
기간: Phase 2: Cycle 1 Day 15
|
Cmax for everolimus was defined as the maximum observed concentration of everolimus in blood following administration of study treatment on Cycle 1 Day 15 and was obtained directly from the measured blood concentration-time curves.
|
Phase 2: Cycle 1 Day 15
|
|
Time to Cmax (Tmax) for Everolimus When Administered Alone or in Combination With Lenvatinib
기간: Phase 2: Cycle 1 Day 15
|
Tmax for everolimus was the amount of time taken after administration of study treatment on Cycle 1 Day 15 to reach the maximum concentration (Cmax) of everolimus in blood.
|
Phase 2: Cycle 1 Day 15
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
일반 간행물
- Lee CH, Motzer RJ, Glen H, Michaelson MD, Larkin J, Minoshima Y, Kanekiyo M, Ikezawa H, Sachdev P, Dutcus CE, Funahashi Y, Voss MH. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. Br J Cancer. 2021 Jan;124(1):237-246. doi: 10.1038/s41416-020-01092-0. Epub 2020 Oct 7.
- Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16(15):1473-1482. doi: 10.1016/S1470-2045(15)00290-9. Epub 2015 Oct 22. Erratum In: Lancet Oncol. 2016 Jul;17 (7):e270. Lancet Oncol. 2018 Oct;19(10):e509.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2010년 8월 5일
기본 완료 (실제)
2014년 6월 13일
연구 완료 (실제)
2018년 2월 8일
연구 등록 날짜
최초 제출
2010년 5월 26일
QC 기준을 충족하는 최초 제출
2010년 6월 2일
처음 게시됨 (추정)
2010년 6월 3일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2019년 2월 27일
QC 기준을 충족하는 마지막 업데이트 제출
2019년 2월 7일
마지막으로 확인됨
2018년 1월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- E7080-G000-205
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
전이성 신장 세포 암종에 대한 임상 시험
-
Taichung Veterans General Hospital완전한심장 독성 | 비소세포폐암 (MeSH 용어: Carcinoma, Non-Small-Cell Lung) | 의약품 관련 부작용 및 이상반응 (MeSH 용어) | Egfr 티로신 키나아제 억제제대만
-
Fondazione del Piemonte per l'Oncologia모병유방암 | 난소 암 | 대장암 | 흑색종(피부암) | 비소세포폐암 (MeSH 용어: Carcinoma, Non-Small-Cell Lung)이탈리아
Lenvatinib에 대한 임상 시험
-
Sun Yat-sen University모병
-
Shanghai Zhongshan Hospital아직 모집하지 않음
-
The First Affiliated Hospital with Nanjing Medical...아직 모집하지 않음
-
Sun Yat-sen University모집하지 않고 적극적으로
-
Second Affiliated Hospital of Guangzhou Medical...모병